News | May 18, 2021
Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
India sales grew 23.5% YoY with consolidation of Wockhardt products
India sales grew 23.5% YoY with consolidation of Wockhardt products
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Subscribe To Our Newsletter & Stay Updated
